Dimitrios Mougiakakos
Overview
Explore the profile of Dimitrios Mougiakakos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
5355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D, et al.
Mol Cancer
. 2025 Mar;
24(1):69.
PMID: 40050933
Cancer-associated myeloid cells due to their plasticity play dual roles in both promoting and inhibiting tumor progression. Myeloid cells with immunosuppressive properties play a critical role in anti-cancer immune regulation....
2.
Jantz-Naeem N, Guvencli N, Bottcher-Loschinski R, Bottcher M, Mougiakakos D, Kahlfuss S
Am J Physiol Cell Physiol
. 2025 Feb;
328(3):C1062-C1075.
PMID: 39946684
It is well known that T-cell metabolism and function are intimately linked. Metabolic reprogramming is a dynamic process that provides the necessary energy and biosynthetic precursors while actively regulating the...
3.
Zeremski V, Haage T, Mougiakakos D
Neurooncol Pract
. 2025 Feb;
12(1):168-172.
PMID: 39917755
Background: Despite recent significant advances, the treatment of elderly patients with primary central nervous system lymphoma (PCNSL) is still challenging due to comorbidities, poor baseline performance status (PS), and drug...
4.
Trautmann-Grill K, von Bonin M, Georgi A, Middeke J, Bottcher M, Meyer O, et al.
Lancet
. 2025 Jan;
405(10472):25-28.
PMID: 39755385
No abstract available.
5.
Mougiakakos D, Meyer E, Schett G
Blood
. 2024 Dec;
PMID: 39700499
The advent of chimeric antigen receptor (CAR) T-cells has revolutionized the treatment landscape for hematologic malignancies, and emerging evidence suggests their potential in autoimmune diseases (AIDs). This article examines the...
6.
Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, et al.
Cytotherapy
. 2024 Nov;
27(2):236-246.
PMID: 39530971
Background: B-cell targeting chimeric antigen receptor (CAR) T-cell therapies, which lead to profound B-cell depletion, have been well-established in hematology-oncology. This deep B-cell depletion mechanism has prompted the exploration of...
7.
Mougiakakos D
Signal Transduct Target Ther
. 2024 Oct;
9(1):276.
PMID: 39379353
No abstract available.
8.
9.
Schett G, Muller F, Taubmann J, Mackensen A, Wang W, Furie R, et al.
Nat Rev Rheumatol
. 2024 Aug;
20(9):531-544.
PMID: 39107407
Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients...
10.
Schett G, Mackensen A, Mougiakakos D
Lancet
. 2024 Jul;
404(10450):336-337.
PMID: 39067897
No abstract available.